Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (July 2024)
24 slides from Evofem Biosciences's investor presentation, Jul 18, 2024
Slide 1: Investor Presentation
BIOSCIENCES INVESTOR PRESENTATION suty 17, 2024 ba)
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘This presentation contains forward looking statements within the meaning af The Peuat Securities Litigation Reform Ae of 1995 and other federal securities laws. n some cases, you can deni fad looking statements by terms such as may "wil “should” “expect” “pln “alm” “antic
Slide 3: Evofem: Women's Sexual and Reproductive Health Innovation
EVOFEM: WOMEN’S SEXUAL AND REPRODUCTIVE HEALTH INNOVATION * U.S. biopharma company commercializing innovative products to address unmet needs in women’s sexual and reproductive health * Hormone-free, on-demand prescription contraceptive vaginal gel $18.2M net sales in 2023 pene — * FDA-approved sing
Slide 4: 43.3M Potential Phexxi Users in the U.S.
herr? 43.3M POTENTIAL PHEXXI USERS IN THE U.S.1 (lactic acid, civic acd, and potassium bitartrate) Vagina) Gal 1,8%6,1%,0.4% Prescription Contraceptive 200 ‘Surgical sterilization 172 8 2. Grandin Reseseh US. cotacetive Marat Si, hte Trends sna Repo By roduc Pl tavern Daves (UD), Consomy, Vap 10.3M
Slide 5: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION Innovative women’s reproductive and sexual health solutions THE FIRST AND ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL * Vaginal pH Modulator Hormone-free FDA-approved for prevention of pregnancy Woman-controlled Used only when you need it Box
Slide 6: MOA - Phexxi Is a pH Modulator
MOA - PHEXXI IS A pH MODULATOR Optimal vaginal pH levels can range from 3.5 -4.5 Allows sperm to be mobile and swim up the reproductive canal This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions
Slide 7: Every 1% Market Share of the 43.3M Women in Our Addressable Market
EVERY 1% MARKET SHARE OF THE 43.3M WOMEN IN OUR ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES Paid by the plan, not the woman GROSS WAC sic eure $348.24! Under Federal law, most payers must cover FDA-approved is ee contraceptives, including Phexxi, at no cost to women Gross-to-Net Adju
Slide 8: Net Product Sales Growth Since Launch
NET PRODUCT SALES GROWTH SINCE LAUNCH e fort (. Three consecutive years of revenue growth $18.2 $16.8 “ $8.2 =a | | F — FY 2020 FY 2021 FY 2022 FY 2023 IN MILLIONS,
Slide 9: Net Sales Consistently Surpass Sales & Marketing Cost
NET SALES CONSISTENTLY SURPASS SALES & MARKETING COST Quarterly selling and marketing expense as a percent of net product sales os a as 360 | | . a2202 93202 204% 188% $19.7 538 $38 l] 25 522 12028 2203 66% 89% $5 1 a 93208 58% @ Product sales, net m Selling and Marketing $48 535 fl | $23 enzo enzo
Slide 10: Activating Select Patient Types to Use Phexxi
ACTIVATING SELECT PATIENT TYPES TO USE PHEXxXI a NOT USING A PRESCRIPTION ‘CONTRACEPETIVE Targeting women who are aligned with the current Phexxi iG WITH user profiles | DEPRESSION AND ANXIETY Capitalizing on where Phexxi is | POSTPARTUM MOTHER: already performing STRUGGLES WITH HER WEIGHT IN NEED O
Slide 11: Activating Phexxi Utilization with Select Patient Types
ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES fers! - < oo. ' flees cite aid, and Prior Contraception Among Women Switching to Phexxi: pe otassium bitartrate) Vaginal Ge 1.8%, 1%,0.4%. 80.6% 1.7% Were not on any method of ‘Switching from hormonal Ax contraception rings and patches 9.99 eo:
Slide 12: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal BIRTH CONTROL IS PERSONAL. METHOD" MEETS YOUR NEEDS?
Slide 13: The GLP-1 Opportunity
THE GLP-1 OPPORTUNITY GLP-1s include Ozempic, Wegovy, Mounjaro, and Zepbound GLP-1s may make oral birth control pills less effective at certain points in dosing schedule Mounjaro and Zepbound clearly instruct HCPs to “advise females using oral contraceptives to switch to a non- oral contraceptive me
Slide 14: GLP-1 U.S. Opportunity: $224.56 Million TAM
GLP-1 U.S. OPPORTUNITY: $224.56 MILLION TAM 30M 2030 Forecast (U.S.) GLP-1 Users Women of Reproductive Age as % of U.S. Adult Population Female GLP-1 Users of Reproductive Age % of Women of Reproductive Age using Oral Contraceptives (OCs) : 11M Women on GLP-1s using OCs . foot targets $224.56 M Net
Slide 15: Phexxi Sales Coverage
PHEXXI SALES COVERAGE LJ Field Coverage (n=16) Virtual Coverage @ | strategic initiatives TET | student Health & Residency Programs j susan
Slide 16: Increasing Phexxi Access
INCREASING PHEXXI ACCESS More than 82% of Phexxi claims are now being approved? YTD 2023 Evofem has gained Phexxi coverage for more than 21.3M new lives! We have 73% coverage within our Commercial and Medicaid books of business? * 19.2M lives covered at no out-of-pocket cost! Co-pay card utilization
Slide 17: Five Orange Book Listed Patents Protect Phexxi Into at Least 2033
FIVE ORANGE BOOK LISTED PATENTS PROTECT PHEXXI INTO AT LEAST 2033 PATENT NO 11,992,472 U.S. INTELLECTUAL PROPERTY PATENT COVERAGE DETAILS DURATION (EXPECTED INTO, AT LEAST) Composition of matter patent covering composition and methods for contraception with a composition that encompasses Phexxi Marc
Slide 18: Synergistic Women's Health Acquisition
SYNERGISTIC WOMEN’S HEALTH ACQUISITION solosec mm secnidazole * Acquired in July 2024 from Lupin Limited * Synergistic women’s health product * Aligns with mission and women’s health call point * Both SOLOSEC and Phexxi address the vaginal biome * Leverages sales force * Detailing by our sales team
Slide 19: SOLOSEC (Secnidazole) Oral Granules
SOLOSEC® (SECNIDAZOLE) 2 G ORAL GRANULES — A novel, differentiated drug to treat two common women’s health infections solosec * “One-and-done” oral, single dose treatment * FDA-approved for two sexual health indications * Solid monthly TRx growth pre-Covid; not consistently promoted since * Good pay
Slide 20: SOLOSEC: Two FDA-Approved Indications
SOLOSEC: TWO FDA-APPROVED INDICATIONS — |, BACTERIAL VAGINOSIS (BV) IN FEMALES 12 AND oLpeR SQIOSEC == secnidazole ° Affects ~21 million women in the U.S. BV affects * Most common vaginal condition in women ages 15-44 29% of US, population * Results from an overgrowth of bacteria, which upsets the b
Slide 21: SOLOSEC: Two FDA-Approved Indications
SOLOSEC: TWO FDA-APPROVED INDICATIONS — Il. TRICHOMONIASIS IN PEOPLE 12 AND OLDER solosec >= secnidazole * The most common non-viral STI in the world? Trich affects 8.7% of US. population * Caused by a parasite called Trichomonas vaginalis * ~5.4 million infections (U.S., 2018) - 2.1 million women +
Slide 22: SOLOSEC Demonstrated Solid Growth Until COVID-19 Outbreak
SOLOSEC DEMONSTRATED SOLID GROWTH UNTIL COVID-19 OUTBREAK Monthly TRx Volume
Slide 23: Why Evofem? Why Now?
WHY EVOFEM? WHY NOW? Tenacious, Experienced Team Commercializing Innovative Attractive Target Markets Rx Women’s Health Products ‘Asmall percentage of contraceptive market share yields large revenue Robust birth control industry tailwinds F foot —contacernon Hormone-free, woman-controlled; used only
Slide 24: Thank You
E¥OFEM BIOSCIENCES THANK YOU
Evofem Biosciences — Investor Presentation (July 2024) on 6ix